Site Editor
William J. Gradishar, MD, FACP, FASCO
William J. Gradishar, MD, FACP, FASCO
Posted: Wednesday, August 23, 2023
Research results regarding a potential new breast cancer subtype classification, which the authors believe has significant implications for personalized treatment strategies, were presented during the 2023 American Society of Clinical Oncology (ASCO) Breakthrough meeting (Abstract 10). In their work prospectively validating the IRSN-23 model and reproducing previous findings, Yoshiaki Sota, MD, of Osaka University, Suita, Japan, and colleagues discussed the model’s potential ability to help predict chemotherapy efficacy.
“The IRSN-23 model uses DNA microarray analysis of tumor tissue to stratify patients into highly sensitive (genomically predicted responders) or less sensitive (genomically predicted nonresponders) chemotherapy groups based on immune-related gene expression,” explained the team. They used the model first to classify tumor tissues obtained from 143 patients with breast cancer who were undergoing preoperative chemotherapy at Osaka University Hospital as predicted responders or nonresponders and then to assess the model’s ability to predict pathologic complete response.
“In the Osaka University Hospital prospective cohort, the pathologic response rate was significantly higher in the [predicted responders] (29.3%) than in the [predicted nonresponders] (1.4%) without trastuzumab treatment. In all prospective validation cohorts without anti-HER2 therapy, the pathologic response rate in the [predicted responders] was significantly higher than in the [predicted nonresponders],” the investigators stated.
“Collaborative analyses of IRSN-23 Immune Score and OncotypeDx Recurrence Score suggested the identification of a highly sensitive chemotherapy group,” they wrote.
Disclosure: The study authors reported no conflicts of interest.
JNCCN Spotlights
Resources
For your Patients
